Tissue Regenix Group plc
TRX.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.27 | 1.24 | 0.33 | 0.14 |
| FCF Yield | -10.76% | 0.38% | -4.78% | -7.73% |
| EV / EBITDA | 45.16 | 115.17 | -50.72 | -17.52 |
| Quality | ||||
| ROIC | 1.33% | -1.00% | -5.63% | -13.68% |
| Gross Margin | 47.55% | 47.60% | 37.34% | 28.52% |
| Cash Conversion Ratio | 4.17 | -0.61 | 0.64 | 0.70 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.38% | 14.31% | 24.03% | 14.85% |
| Free Cash Flow Growth | -3,322.60% | 107.71% | 41.68% | 42.53% |
| Safety | ||||
| Net Debt / EBITDA | 6.30 | 10.64 | -4.49 | -0.74 |
| Interest Coverage | 0.40 | -0.35 | -2.71 | -6.33 |
| Efficiency | ||||
| Inventory Turnover | 1.07 | 1.49 | 1.19 | 1.22 |
| Cash Conversion Cycle | 330.12 | 261.70 | 335.66 | 266.82 |